Department of Surgery, Lokman Hekim University Medical School, Ankara, Turkey.
Section for Colorectal Surgery, Ankara University School of Medicine, Ibn-I Sina Hospital, Ankara, 06100, Turkey.
Tech Coloproctol. 2023 Jun;27(6):465-474. doi: 10.1007/s10151-023-02751-z. Epub 2023 Jan 18.
Long-term bowel dysfunction after resection for rectal cancer, known as low anterior resection syndrome (LARS), is observed in many patients. The LARS score was developed to assess this syndrome and its impact on the quality of life in Danish patients. Recently versions in English and many other languages have been validated. The aim of this study was to validate the Turkish translation of the LARS score in patients who have undergone treatment for rectal cancer.
Rectal cancer patients who underwent low anterior resection in May 2000- May 2018 in three Turkish centers received the LARS score questionnaire, the European Organisation for Research and Treatment Of Cancer Core Quality of Life questionnaire [Ed.11] (EORTC QLQ-C30), and a single ad hoc quality of life question. The test-retest reliability of the LARS score was evaluated by asking a randomly selected subgroup of patients to repeat the assessment of the LARS score 2 to 4 weeks after their initial response.
A total of 326 patients were reviewed and contacted for the study, and 222 (68%) were eligible for the analyses (129 males, 93 females, median age 64 years [range:24-87 years, IQR = 14]) There was a strong association between the LARS score and quality of life (p < 0.01) and the test-retest reliability was high. The intraclass correlation coefficient was 0.78 (95% CI 0.73-0.83) for the whole study group and 0.79 (95% CI 0.68-0.87) for the subgroup, indicating strong reliability.
The Turkish translation of the LARS score has psychometric properties comparable with previously published results in similar studies. The Turkish version of the LARS score can be considered a valid and reliable tool for measuring LARS in Turkish rectal cancer patients.
NCT05289531.
直肠癌切除术后长期的肠道功能障碍，即低位前切除综合征（LARS），在许多患者中可见。LARS 评分用于评估丹麦患者的这种综合征及其对生活质量的影响。该评分已被翻译成英文和许多其他语言，并得到了验证。本研究旨在验证已用于直肠癌治疗的土耳其语版 LARS 评分。
2000 年 5 月至 2018 年 5 月，在土耳其的 3 个中心接受低位前切除术的直肠癌患者接受了 LARS 评分问卷、欧洲癌症研究与治疗组织核心生活质量问卷[第 11 版]（EORTC QLQ-C30）和一个单独的特定生活质量问题。通过让随机选择的亚组患者在初次应答后 2 至 4 周重复评估 LARS 评分，评估 LARS 评分的测试-重测信度。
共回顾和联系了 326 名患者，其中 222 名（68%）符合分析条件（男性 129 名，女性 93 名，中位年龄 64 岁[范围：24-87 岁，IQR=14]）。LARS 评分与生活质量之间存在很强的相关性（p<0.01），测试-重测信度较高。整个研究组的组内相关系数为 0.78（95%CI 0.73-0.83），亚组为 0.79（95%CI 0.68-0.87），表明信度较高。
土耳其语版 LARS 评分具有与类似研究中先前发表的结果相当的心理测量特性。土耳其语版 LARS 评分可被视为测量土耳其直肠癌患者 LARS 的有效和可靠工具。
NCT05289531。
